DDrare: Database of Drug Development for Rare Diseases

5. 進行性核上性麻痺
［臨床試験数：82，薬物数：107（DrugBank：36），標的遺伝子数：60，標的パスウェイ数：90］

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03625128 (ClinicalTrials.gov)	January 2, 2018	12/7/2018	18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls	Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls	Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment	Drug: F-18	Chang Gung Memorial Hospital	NULL	Completed	20 Years	90 Years	All	36	Early Phase 1	Taiwan
2	EUCTR2017-000094-36-SE (EUCTR)	31/03/2017	30/01/2017	The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders	The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders	Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Product Name: 18F-RO6958948 Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl	Skåne University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Sweden
3	NCT02605785 (ClinicalTrials.gov)	November 2015	3/11/2015	A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy	A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy	Progressive Supranuclear Palsy	Drug: F-18 AV 1451	Mayo Clinic	NULL	Recruiting	40 Years	N/A	All	134	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03625128
(ClinicalTrials.gov)

January 2, 2018

12/7/2018

18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment

Drug: F-18

Chang Gung Memorial Hospital

NULL

Completed

20 Years

90 Years

All

Early Phase 1

Taiwan

EUCTR2017-000094-36-SE
(EUCTR)

31/03/2017

30/01/2017

The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders

The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders

Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl

Skåne University Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Sweden

NCT02605785
(ClinicalTrials.gov)

November 2015

3/11/2015

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Drug: F-18 AV 1451

Mayo Clinic

NULL

Recruiting

40 Years

N/A

All

134

N/A

United States